1800 202 8726
Premalignant lesions

Surveillance vs Treatment — for Premalignant Lesions

When a test finds a premalignant lesion, the result can feel like an open question rather than an answer. Some lesions need treatment now. Others need a structured monitoring plan. Which applies to you depends on factors your team weighs for your specific finding.

Medically reviewed by Dr. Mohammed Imaduddin, Surgical Oncologist, MBBS · MS (General Surgery) · M.Ch (Surgical Oncology) · Last reviewed September 2026

  • Watching is not ignoring — Surveillance follows a plan with defined intervals and specific things the team looks for. Missing appointments removes the safety mechanism.
  • Grade is the starting point — Whether cellular changes are low-grade or high-grade is usually the first factor in the decision, but it is not the only one.
  • Same diagnosis, different plans — Two people with the same type of premalignant lesion may receive different recommendations depending on their full clinical picture.
  • The plan can change — If a lesion progresses during surveillance, the recommendation is reassessed. Stability or regression can also prompt a change.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Talk to a medical oncologist

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

The decision between surveillance and treatment depends on the grade of cellular change, how fast it is progressing, where it sits in the body, and your overall health. Neither option is automatically right. Your oncologist weighs whether the risk of the lesion outweighs the risk of the intervention, for you specifically.

When is watching the right approach?

Surveillance is recommended when cellular changes are low-grade and the lesion has a slow or uncertain progression rate. In these situations, the risk of treating immediately — which may involve a procedure with its own side effects — can outweigh the benefit of acting now.

Watching is also appropriate when the lesion is in a location where intervention carries significant risks, or when your overall health means a procedure would be more burdensome than the lesion at its current stage.

Surveillance is not passive care. It follows a structured schedule with defined check-up intervals and clear criteria for what the team is looking for at each visit.

When is treatment the right approach?

Treatment is typically recommended when the grade of cellular change is high, when a lesion is progressing between check-ups, or when it has features that suggest a higher likelihood of becoming invasive.

The site matters. In some locations, even a lower-grade lesion may be treated earlier because the consequences of progression are harder to reverse, or because monitoring access is limited.

Your age, other health conditions, and ability to attend regular follow-up all factor into the recommendation. A plan that is right for one person may not be right for another with the same diagnosis.

Not sure what this means for you?

Share your reports and a senior oncologist will explain your options in plain language — no obligation to start treatment.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

How does your team make this decision?

The decision is made by weighing the likely behaviour of the lesion against the risks of the available interventions. It is not a formula, and it is not a one-time answer — it is reassessed at each follow-up visit.

Many premalignant findings are discussed at a multidisciplinary team meeting, where specialists in pathology, surgery, radiology, and oncology review the case together rather than one doctor deciding in isolation.

If you are unsure about the recommendation, asking for the reasoning in plain terms is entirely reasonable. You should know what is being watched for, why it matters, and what would prompt a change in plan.

What do these medical terms mean?

Surveillance
Regular check-ups at defined intervals to see whether a lesion changes. It follows a plan, and each visit looks for specific things.
Low-grade dysplasia
Cellular changes that look mildly abnormal under a microscope but remain far from cancer. These often stay stable or revert over time.
High-grade dysplasia
More severe abnormality closer to the boundary with invasive cancer. High-grade changes are more likely to be treated rather than monitored.
Progression
A lesion showing more severe changes at a follow-up visit than at the previous one. Progression typically prompts a reassessment of the treatment plan.
Regression
A lesion improving or resolving on its own during surveillance. This occurs with some types of premalignant lesion and is part of why monitoring is sometimes the preferred first step.

Did you know?

The word 'premalignant' describes a risk category, not an individual prediction. It means cells have changed in ways that increase the likelihood of cancer over time — not that cancer is inevitable, and not that it has already started.

Whether and how fast a specific lesion might progress can be estimated only in ranges, which is why clinical guidance from bodies such as ESMO and NCCN accounts for individual circumstances rather than treating every finding the same way.

Source: ESMO Clinical Practice Guidelines; NCCN Guidelines: Cancer Prevention and Early Detection

Explore 102 more Your Result, What Comes Next and Support topics

HUB — Who Can Have a Biopsy? Special Situations

HUB — Your Biopsy Confirmed Cancer

All Your Result, What Comes Next and Support →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Does choosing surveillance mean my doctor thinks it is not serious?

No. Surveillance is a clinical decision, not a signal that the finding has been downgraded. It means the evidence supports monitoring over immediate intervention for this grade of change, in this location, for you specifically. The check-up schedule — how often you are seen and what is examined each time — reflects how seriously the finding is being taken.

Can I ask to be treated rather than watched, or vice versa?

You can always ask for the reasoning behind the recommendation and ask what the alternative would involve. Your oncologist will explain why one approach is preferred for your specific lesion. A recommendation to watch is not the same as saying either option is equally appropriate — the clinical reasoning matters, and you deserve to understand it before any decision is made.

How often will I need to come back for check-ups?

The interval depends on the type and grade of the lesion, the site, and the specific guideline your team follows. Some surveillance schedules call for three-monthly visits; others are annual. Your team should tell you the interval, what happens at each visit, and what would change the plan. If this was not explained at your last appointment, ask at the next one.

What happens if the lesion gets worse during surveillance?

Progression during surveillance changes the picture. Your team will reassess whether treatment is now the right step, and if so, what kind. The surveillance plan exists partly to catch progression early, when options tend to be most straightforward. This is why attending every scheduled visit matters — the safety of monitoring depends on not missing those check-ups.

Can a premalignant lesion improve or disappear on its own?

Yes, in some types of premalignant lesion. Regression — where cellular changes become less severe or resolve entirely without treatment — does occur and is documented in the medical literature for several lesion types. It is part of why surveillance is sometimes chosen over immediate intervention. It is not something to count on, but it is a recognised part of the natural history of some premalignant conditions.

Does having a premalignant lesion mean I will develop cancer?

No. A premalignant label describes a risk category, not a certainty for any individual. Many people with premalignant lesions never develop cancer — some lesions remain stable for years, and some regress. The risk is real enough to monitor carefully, but it is a statistical likelihood across a group, not a personal prediction. Your oncologist can explain what is known about your specific lesion type, and what your follow-up plan is designed to detect.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation